The effect of HCV serological status on Doxorubicin based chemotherapy induced toxicity and disease-free survival in breast cancer patients

Karim Yousri Welaya a,*, Shabaan El-Assal a, Ossama Eisa Salama b, Hamdy Mohamad Ghanem a, Salah-Eldin Abdelmoneim a

a Clinical Oncology Department, Alexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt
b Public Health Department, Alexandria Faculty of Medicine, Alexandria University, Alexandria, Egypt

Received 19 May 2014; accepted 5 August 2014
Available online 10 September 2014

Keywords: Adjuvant chemotherapy; Anthracyclines; Operable breast cancer; HCV; Special populations

Abstract  Background: Breast cancer and HCV are two frequent diseases in Egypt. There is a considerable probability of concurrent affection. This concurrence creates a subpopulation, which needs special evaluation and care.
Objective: To evaluate a subset of Egyptian breast cancer patients receiving Doxorubicin based adjuvant chemotherapy, with HCV seropositivity (group 2) compared to HCV seronegative patients (group 1).
Methods: 102 breast cancer patients, planned to receive Doxorubicin based adjuvant chemotherapy, at the Oncology Department, Alexandria Faculty of Medicine, were recruited since June 2009. Pretreatment evaluation included serological testing for HCV. FAC Adjuvant chemotherapy was given for six cycles.
Results: HCV seropositivity was detected in 52 cases. Two cases in the seropositive group developed toxic hepatitis and discontinued treatment and follow up. The remaining 100 patients suffered comparable toxicities, except for more frequent liver enzyme elevations in the seropositive group. Diarrhea was also more frequent in the seropositive group. Treatment delays and dose reductions were more frequently observed in the seropositive group. The 36 month disease-free survival and relapse pattern were not significantly different between the two groups.

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; NCI, National Cancer Institute; IRB, Institutional Research Board; LVEF, left ventricular ejection fraction; IDC, infiltrating duct carcinoma; ILC, infiltrating lobular carcinoma; FAC, 5-fluorouracil Doxorubicin and cyclophosphamide.
* Corresponding author.
Peer review under responsibility of Alexandria University Faculty of Medicine.

http://dx.doi.org/10.1016/j.ajme.2014.08.001
2090-5068 © 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights reserved.
1. Introduction

Breast cancer is a major medical problem with significant public health and societal ramifications. It is the most common cancer in women. In the latest cancer statistics published by the American Cancer Society in early 2014, the incidence of breast cancer in the United States is over 230,000 cases each year and it is responsible for over 40,000 deaths. Breast cancer incidence rates are highest in more developed countries with lower incidence in less developed countries.

In a hospital-based Egyptian cancer statistics report of the NCI (Cairo), breast cancer constituted 18.9% of total cancer cases (35.1% in women and 2.2% in men) and was the most common cancer among women in this series. The diagnosis was made at a younger median age than in European and North American countries, with a relatively advanced tumor presentation. Such a disease profile emphasizes the role of systemic treatment in the multidisciplinary management of breast cancer patients in Egypt.

The Early Breast Cancer Trialists’ Collaborative Group overview of adjuvant chemotherapy trials has shown an increase in survival benefit over time from polychemotherapy versus no adjuvant chemotherapy, twice as great at 15 years as it was at five years (10 versus 4.7%).

Among the most widely used adjuvant chemotherapy regimens, anthracycline-based therapy has become a standard, unless the patient had a contraindication to anthracyclines. Toxicities from adjuvant chemotherapy must be weighed in the balance between the survival gains versus quality of life impact in premenopausal and postmenopausal patients.

1.1. Chemotherapy and liver disease

Chemotherapy can have a direct hepatotoxic effect or may trigger a worsening of preexisting liver disease, especially viral hepatitis. Conversely, a diseased liver will result in alteration of the metabolism and excretion of chemotherapy drugs that rely upon the liver for their clearance. This can result in increased systemic toxicity or worsening of chemotherapy-induced hepatotoxicity. Cyclophosphamide is metabolized by the liver to the cytotoxic metabolite. It is infrequently hepatotoxic. Increased toxicity has not been reported in patients with hepatic dysfunction.

Doxorubicin is extensively metabolized in the liver; and 80% of each dose is excreted in the bile. Isolated case reports have suggested that Doxorubicin can cause hepatotoxicity. Patients with cholestasis have delayed clearance of Doxorubicin and its metabolites and develop greater systemic toxicity from standard doses.

5-Fluorouracil is metabolized in tissues to its active form. Approximately 10% of administered 5-FU is excreted unchanged in the urine, while the remainder is enzymatically catabolized primarily in the liver. Rare reports of hepatotoxicity have been noted with intravenous 5-fluorouracil.

Liver injury is primarily assessed by liver function tests. Radiological studies may be needed to differentiate drug toxicity from biliary, vascular, or tumor-related conditions. Criteria have been developed to grade the severity of treatment-related abnormalities in liver function tests and adjust the dose in patients undergoing chemotherapy.

1.2. Hepatitis C virus

HCV infection has become an increasingly serious health problem in different parts of the world. Egypt has possibly one of the highest HCV prevalence rates in the world. HCV is the leading cause of HCC and chronic liver disease in the country. It is reported that more than 50% of infected people are unaware of their disease, leading to the spread of infection and lost treatment opportunities.

Modern serological HCV diagnostic tests have good sensitivity and specificity particularly in high risk patient groups and their use for screening in these populations has been recommended. Given the prevalence rates of HCV and breast cancer in Egyptians, a significant chance of a concurrent affection is present and warrants screening in breast cancer cases planned for treatment.

This study was conducted to evaluate the experience of Egyptian breast cancer patients receiving Doxorubicin based adjuvant chemotherapy, in association with HCV seropositivity compared to HCV seronegative patients.

2. Patients and methods

This observational cohort study was conducted after the approval of the IRB of Alexandria Faculty of Medicine in April 2009 (IRB No: 00007555-FWA No: 00018699). It included a total of 102 pathologically proven breast cancer patients, recruited since June 2009, who were planned to receive Doxorubicin based adjuvant chemotherapy, at the Oncology Department, Alexandria Faculty of Medicine, Alexandria University. They were chosen according to the following criteria:
1. World Health Organization (WHO) performance status 0–2.23
2. Adequate bone marrow function (white blood cell count > 3000/dl).
3. Platelet count > 100,000/dl and hemoglobin > 9gm/dl.
4. Adequate liver and renal functions (≤1.5 times the upper limit of normal).
5. Age 20–70 years at the time of inclusion.
6. A signed consent obtained from each patient before inclusion in this study, as required by the IRB.
7. LVEF more than 50% measured by echocardiography.

Patients were excluded, if they had one or more of the following conditions:

1. Pregnancy and lactation.
2. Any cardiac disease, or a serious medical or psychiatric condition.
3. Previous liver disease or primary or secondary hepatic malignancy.

All patients included in this study were subjected to pre-treatment clinical, radiological and laboratory evaluation, including peripheral blood count, kidney and liver function tests. HCV antibody testing using Enzyme Linked Immunosorbent Assay (ELISA) was performed on all the patients and accordingly they were classified into 2 groups, the first group included 50 HCV negative patients (group 1) and another group including 52 HCV positive patients (group 2).

All patients were intermediate and high risk breast cancer and were planned to receive anthracycline chemotherapy in the adjuvant setting which started from 4–6 weeks after surgery. The surface area was calculated in both groups by the formula of Mosteller using both the weight and height of each patient to calculate the dose of chemotherapy given to each patient. All patients received CAF regimen (cyclophosphamide 500 mg/m², adriamycin 50 mg/m² and 5-flourouracil 500 mg/m²) given intravenously on day 1 of each cycle. The cycles were repeated every 21 days for a total of 6 cycles. All patients received antiemetic premedication with Ondansteron, Ranitidine and Dexamethasone by intravenous route, 15 min before starting the chemotherapy.

On day 1 of each cycle, each patient was assessed clinically and by laboratory investigations including peripheral blood count, serum kidney and liver function tests. Toxicities were recorded according to the Common Terminology Criteria Adverse Event version 4.23 Dose modifications and/or treatment delay if needed were done according to the laboratory findings, with the guidelines for each individual drug.23 Ejection fraction was measured after finishing the six cycles. An estimate of the average dose given to each group was calculated, with compensation for the average delay per patient, considering a relative effective dose reduction of 25% of a cycle dose for a 1 week delay of that cycle.26

Statistical analysis was performed using SPSS/Win version 16. Chi square and Fisher’s Exact test (if Chi Square test is not applicable in 2x2 tables) were done for non-parametric evaluation of data. Odds ratio and 90% confidence interval were calculated for comparing odds of toxicity and delay endpoints. Multiple linear regression was done on factors affecting liver enzyme levels in each cycle. Analysis included HCV status, age, diabetic status, hypertension and menstrual status. For each cycle there was a model which was analyzed for significance. Kaplan Meier disease-free survival curves were plotted.

3. Results

One hundred and two patients were included in the study. Fifty of them were HCV seronegative (group one) and fifty-two were HCV seropositive (group two). Patient characteristics were comparable in both groups with no statistically significant difference (Table 1).

3.1. Chemotherapy induced toxicity

3.1.1. Laboratory toxicity

There was no statistically significant difference between both groups regarding the frequency and grade of anemia, neutropenia or thrombocytopenia throughout the course of treatment. All patients experienced anemia but none reached grade 3 throughout the course. Grades 3–4 neutropenia were observed after the fifth cycle in 10% (five patients) and 4% (two patients) of group one and two respectively. Grade 1 thrombocytopenia was observed in four patients, two in each group, and was reversible.

Most patients did not suffer any renal impairment. One patient in group two had elevated serum creatinine and blood urea. It reached grade 2 after the first, fourth and fifth cycles but it was still controlled with increased fluid intake. Four other patients had transient elevated blood urea and creatinine, one of them in group one and none of them exceeded grade 1.

<table>
<thead>
<tr>
<th>Table 1 Patient characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number</td>
</tr>
<tr>
<td>Male:female</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Comorbidities</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Pretreatment LVEF (%)</td>
</tr>
<tr>
<td>Stage</td>
</tr>
<tr>
<td>Stage I</td>
</tr>
<tr>
<td>Stage II</td>
</tr>
<tr>
<td>Stage III</td>
</tr>
<tr>
<td>Pathology</td>
</tr>
<tr>
<td>IDC</td>
</tr>
<tr>
<td>ILC or mixed</td>
</tr>
<tr>
<td>Grade</td>
</tr>
<tr>
<td>Well differentiated</td>
</tr>
<tr>
<td>Moderately differentiated</td>
</tr>
<tr>
<td>Poorly differentiated</td>
</tr>
<tr>
<td>Hormone receptor positivity</td>
</tr>
<tr>
<td>HCV seropositivity</td>
</tr>
<tr>
<td>Average body surface area</td>
</tr>
</tbody>
</table>

LVEF: left ventricular ejection fraction.
IDC: infiltrating ductal carcinoma.
ILC: infiltrative lobular carcinoma.
HCV: hepatitis C virus.
Two patients in group two had grade 2 SGOT and SGPT elevation, with manifestations of severe toxic hepatitis. The liver profile for these two patients was not corrected by liver support and they discontinued their chemotherapy. Differences between the two groups in the grade and frequency of liver enzyme elevations started to be significant after the third cycle of chemotherapy (Figs. 1 and 2). Throughout the whole six cycles of chemotherapy, 42% (twenty-one patients) of group two patients developed elevated SGOT compared to 28% in group one (OR = 4.125, 90% CI: 1.8742–9.0788), all of these patients were grade 1 and 2. As regards SGPT level, 34% of patients in group two had elevated SGPT level compared to 18% in group one (OR 3.777 with 90% CI from 1.8846 to 7.5728). None of the study population, who continued for the 6 cycles, experienced any levels of elevated bilirubin except for one patient in group two who had grade 1 transient elevation after the sixth cycle.

3.1.2. Clinical toxicity

Nausea was the most common side effect in the whole studied population. It was more frequent in group one patients. The incidence of high grade nausea was similar in both groups, except after the fourth cycle, where 28% (fourteen patients) and 6% (three patients) had grade 3 nausea in group one and two respectively ($p < 0.001$).

Vomiting was the second common side effect among the studied population. The incidence of high grade vomiting was statistically similar in both groups as 44% of the patients in group one had grade 3–4 compared to 40% in group two throughout the whole cycles.

Diarrhea was the clinical toxicity showing the most significant difference between both groups regarding the clinical toxicity profile (Fig. 3). Overall, 28% of the patients in group two experienced grade 3–4 compared to 4% only in group one through the six cycles of chemotherapy. (OR = 14.636, 90% CI 5.5084–38.8902).

Grade 3 stomatitis was more common in group one patients (20% versus 16%). The incidence of stomatitis was higher in group one after cycle V where 62% (thirty-two patients) had stomatitis compared to 44% (twenty-two patients) in group two. This was also observed after the sixth cycle where the incidence of stomatitis was 62% and 48% in group one and two respectively (OR = 5.9341, 90% CI: 2.6278–13.4005).

Mild Skin changes, including skin discoloration and nail changes, not exceeding grade 2, were more frequent in group one and increased steadily throughout the course of treatment. By the end of the sixth cycle, 100% and 98% of patients of group one and group two respectively had grade 2 alopecia.

After six cycles, cardiac toxicity in terms of grade 1 change in ejection fraction was observed in 70% and 58% of group one and group two respectively, but the difference was not statistically significant ($p = 0.211$).

3.2. Dose delay and modification

In group one, the range of the overall treatment duration was 15–19 weeks, while in group two the range of the overall treatment duration was a bit wider ranging from 15 to 21 weeks (Fig. 4). The majority of patients in both groups finished their treatment on time. The number of patients with delays was higher in group two (52%) than in group one (36%), excluding
the two patients in group two, who had severe toxic hepatitis after the first cycle and discontinued chemotherapy. HCV sero-
negativity was associated with a lower risk of treatment delays,
but the difference is not significant (OR = 0.5192, 90%
CI = 0.2651–1.0168).

Fig. 5 demonstrates that 50% of the patients in group one
finished their course without delays or dose modification com-
pared to 32% in group two, with OR = 2.125 (90%
CI = 1.0744–4.2031). OR for delay > 17 weeks, in spite of dose
modification (in HCV negative patients) = 0.3459 (90%
CI = 0.15–0.7977).

Fig. 5  Treatment delay > 17 weeks and dose modification
OR for no delay and no dose modification = 2.125 (90%
CI = 1.0744–4.2031). OR for delay > 17 weeks, in spite of dose
modification (in HCV negative patients) = 0.3459 (90%
CI = 0.15–0.7977).

Fig. 4 Overall treatment duration in groups 1 and 2. OR = 0.5192 (90% CI = 0.2651–1.0168).

Fig. 6 shows the mean percentage of the dose given for each
drug throughout the six cycles in both groups. The difference
between both groups is best demonstrated in the Doxorubicin
dose graph, which is considered to be the most hepatotoxic of
the three components of the protocol. The dose given for all
the studied population is gradually reduced in each consecutive
cycle until reaching the fifth cycle where the difference between
both groups is best demonstrated. The estimate of the average
dose given to each group calculated, with compensation for the
average delay per patient, is reported in Table 2. The maxi-
mum delay and dose reduction affected the Doxorubicin rela-
tive dose. The other 2 drugs were less affected. The average
relative DI of FAC in HCV seropositive patients compared
to seronegative patients is 92%. Multiple linear regression
models were not significant in the first two cycles. After the
third cycle and onward, the model was significant for the level

<table>
<thead>
<tr>
<th>Drug</th>
<th>Relative dose (%)</th>
<th>Relative DI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxorubicin</td>
<td>87</td>
<td>90</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>97</td>
<td>92</td>
</tr>
<tr>
<td>5-Fluorouracil</td>
<td>96</td>
<td>93</td>
</tr>
<tr>
<td>Combined</td>
<td></td>
<td>92</td>
</tr>
</tbody>
</table>
of SGOT and SGPT, where p was <0.01. HCV status was the significant predictor, for SGOT and SGPT increased levels, except for SGPT in cycle 6. Age had an inverse impact on SGOT for cycles 4, 5, and 6. The inverse effect of age on SGPT was apparent in cycles 4 and 6 only.

3.3. Disease-free survival and patterns of recurrence

Of the 100 patients who were able to continue the 6 cycles of chemotherapy, 6 patients in the HCV seronegative group and 15 patients in the HCV positive group were untraced and lost follow up. Kaplan–Meier disease free survival curves (Fig. 7) were plotted for the remaining patients and showed no significant difference between both groups (Log Rank test: 0.260, p = 0.61).

Table 3  Pattern of failure.

<table>
<thead>
<tr>
<th></th>
<th>HCV</th>
<th></th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(n=44)</td>
<td>(n=35)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>Local</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>38</td>
<td>86.36</td>
<td>27</td>
</tr>
<tr>
<td>Yes</td>
<td>6</td>
<td>13.64</td>
<td>8</td>
</tr>
<tr>
<td>Liver</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>34</td>
<td>77.27</td>
<td>24</td>
</tr>
<tr>
<td>Yes</td>
<td>10</td>
<td>22.73</td>
<td>11</td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>34</td>
<td>77.27</td>
<td>28</td>
</tr>
<tr>
<td>Yes</td>
<td>10</td>
<td>22.73</td>
<td>7</td>
</tr>
<tr>
<td>Bone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>39</td>
<td>88.64</td>
<td>29</td>
</tr>
<tr>
<td>Yes</td>
<td>5</td>
<td>11.36</td>
<td>6</td>
</tr>
<tr>
<td>Total relapse</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>22</td>
<td>50.0</td>
<td>15</td>
</tr>
<tr>
<td>Yes</td>
<td>22</td>
<td>50.0</td>
<td>20</td>
</tr>
</tbody>
</table>

4. Discussion

Receiving chemotherapy is a very distressing and concern-provoking stage of the treatment of breast cancer, associated with decrease in overall quality of life.27,28 Endemic HCV infection can be exacerbated with cytotoxic agents.29 HCV positive patients receiving chemotherapy are already burdened with associated comorbidities and may be less tolerant to adverse events of the chemotherapy.30

Fallahian et al. reviewed the literature for viral hepatitis reactivation in immune suppressed patients and patients under chemotherapy. The reviewed studies showed a “less clear relationship between chemotherapy and HCV reactivation than HBV”. Mild abnormalities of liver enzymes were reported. HCV appeared to increase the risk of veno-occlusive disease in transplant patients. The authors advocated the use of HCV antiviral treatment for progressive cases of reactivation.31

Torres and Davila in their review on hepatitis virus reactivation in cancer patients stated that: “HCV reactivation seems to be less common than HBV reactivation and is usually associated with a good outcome and low mortality. However, once severe hepatitis develops, as a result of viral reactivation, mortality rates seem to be similar among patients infected with HBV or HCV. Liver damage owing to viral reactivation frequently leads to modifications or interruptions of chemotherapy, which can negatively affect patients’ clinical outcome”.32

In the current prospective cohort study, the difference in the toxicity profile between HCV seropositive and seronegative patients was mainly observed in the form of more frequent reversible transaminase level elevations and more frequent high grade diarrhea. Two cases developed severe hepatitis precluding any further chemotherapy and were excluded from further analysis. There were more delays in the HCV positive group compared to the HCV negative group (52% versus 36%). High grade neutropenia was more frequent in group 2. There was no clear explanation regarding the high incidence of diarrhea in the HCV positive patients compared to other adverse effects. One reason could be attributed to the findings of Fouad et al. which showed that Irritable bowel syndrome was more frequent in HCV positive patients compared to HBV patients and the normal controls.33

Morrow et al. reported an expansion of their retrospective series analyzing the effects of chronic hepatitis C infection on the treatment of 45 HCV positive breast cancer patients treated in MD Anderson Cancer Center (MDACC). Only 36 patients of the 44 received chemotherapy. Patients received different kinds of regimens including anthracyclines, taxanes, and anthracycline plus taxanes, with or without trastuzumab. This cohort was compared to a HCV negative group (52% versus 36%). High grade neutropenia was more frequent in group 2. There was no clear explanation regarding the high incidence of diarrhea in the HCV positive patients compared to other adverse effects. One reason could be attributed to the findings of Morrow et al. which showed that HCV infection was associated with an increased risk of neutropenia and diarrhea.”34

The toxicity profile in the current series and the ensuing dose reduction/dose delays did not adversely affect the pattern of relapse or disease-free survival. However, this observation should be taken cautiously for two main reasons, firstly is the short term follow up of the patients (36 months), longer
follow up is needed to accurately monitor the effect of dose delay and modification especially in the seropositive group, secondly, the number of untraced cases and their unequal distribution between the two groups may distort the results.

4.1. Conclusion

HCV is an endemic infection in Egypt and all patients receiving chemotherapy should undergo screening for the virus. Most patients with HCV were able to tolerate chemotherapy well and continue the initial chemotherapy plan, without significant change in the toxicity profile or the natural course of their malignancy. Close monitoring of the patients would help diagnose and promptly manage those with less tolerance to treatment. Dose or regimen adjustments may be of help to such patients. A preemptive 10% initial Doxorubicin dose reduction might reduce the frequency of severe toxicity and the consequent dose reductions and delays. It is important to seek the assistance of a hepatologist/gastroenterologist in evaluating any HCV positive breast cancer patient who is planned to receive chemotherapy.

Conflict of interest

None declared.

References